程序性死亡受体-1 与淋巴细胞活化基因-3在滤泡性淋巴瘤中的表达及临床意义

摘要
图/表
参考文献(30)
相关文章 (1)

全文: PDF (1098 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨程序性死亡受体-1（PD-1）、淋巴细胞活化基因-3（LAG-3）在滤泡性淋巴瘤（FL）肿瘤微环境中的表达情况及临床意义。方法选取2017—2022 年中国科学技术大学附属第一医院22 例病理明确诊断为FL 的患者，采用免疫组化方法检测FL 患者标本中PD-1、LAG-3、细胞程序性死亡-配体1（PD-L1）、细胞表面趋化因子受体4（CCR4）、细胞表面趋化因子受体3B（CXCR3B）、叉头蛋白P3 抗体（FOXP3）因子的表达水平，分析PD-1、LAG-3 与FL 患者临床病理特征及预后的关系，并分析各因子间的相关性。结果 PD-1 高表达组和LAG-3高表达组β2 微球蛋白（β2-MG）水平高于低表达组，差异有统计学意义（P＜0.05）；PD-1/LAG-3 双高表达组乳酸脱氢酶（LDH）和β2-MG 水平高于PD-1/LAG-3 单高表达组与PD-1/LAG-3 双低表达组，差异有统计学意义（P＜0.05）。相关性分析显示在FL 组织中，PD-1 表达水平与LAG-3、CCR4、CXCR3B 表达水平呈正相关（r=0.432、0.440、0.506，P＜0.05），而与PD-L1 和FOXP3 表达水平无相关性（P＞0.05）。PD-1 高表达组、LAG-3 高表达组和PD-1/LAG-3 共同高表达组CD8+T 细胞计数少于对应低表达组，差异有统计学意义（P＜0.05），进一步相关性分析结果显示PD-1 表达、LAG-3 表达以及PD-1/LAG-3 共同表达与CD8+T 细胞计数呈负相关（r=-0.631、-0.425、-0.552，P＜0.05）。生存分析结果显示LDH 低表达组的无进展生存期（PFS）和总体生存期（OS）优于高表达组；PD-1 低表达组、LAG-3 低表达组和PD-1/LAG-3 双低表达组的PFS 和OS 优于高表达组，差异有统计学意义（P＜0.05）。结论 PD-1、LAG-3 高表达与FL 患者较高的临床检验指标水平及较差的生存预后相关；PD-1、LAG-3等免疫检查点在肿瘤微环境中共同表达，影响T 细胞计数。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：程序性死亡受体-1, 淋巴细胞活化基因-3, 肿瘤微环境, 滤泡性淋巴瘤

Abstract：

Objective To investigate the expression and clinical significance of programmed death receptor-1 (PD-1)and lymphocyte activation gene-3 (LAG-3) in the tumor microenvironment of follicular lymphoma (FL).Methods A total of 22 patients with FL diagnosed by pathology in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2022 were included.The expression levels of PD-1,LAG-3,programmed cell death-ligand 1 (PD-L1),cell surface chemokine receptor 4 (CCR4),cell surface chemokine receptor 3B (CXCR3B) and forkhead protein P3 antibody(FOXP3)in FL patients were detected by immunohistochemistry.The relationship between PD-1,LAG-3 and clinicopathological features and prognosis of FL patients was analyzed,and the correlation between each factor was analyzed.Results The levels of β2 microglobulin (β2-MG)in PD-1 high expression group and LAG-3 high expression group were higher than those in low expression group,and the differences were statistically significant (P＜0.05).The levels of lactate dehydrogenase (LDH)and β2-MG in PD-1/LAG-3 double high expression group were higher than those in PD-1/LAG-3 single high expression group and PD-1/LAG-3 double low expression group,and the differences were statistically sig-nificant (P＜0.05).Correlation analysis showed that in FL tissues,the expression level of PD-1 was positively correlated with the expression levels of LAG-3,CCR4 and CXCR3B (r=0.432,0.440,0.506,P＜0.05),but not with the expression levels of PD-L1 and FOXP3(P＞0.05).The CD8+T cell count in PD-1 high expression group,LAG-3 high expression group and PD-1/LAG-3 co-high expression group was less than that in the corresponding low expression group,and the differences were statistically significant(P＜0.05).Further correlation analysis results showed that PD-1 expression,LAG-3 expression and PD-1/LAG-3 co-expression were negatively correlated with CD8+T cell count(r=-0.631,-0.425,-0.552,P＜0.05).The results of survival analysis showed that the progression-free survival(PFS)and overall survival(OS)of LDH low expression group were better than those of LDH high expression group,and the PFS and OS of PD-1 low expression group,LAG-3 low expression group and PD-1/LAG-3 double low expression group were better than those of high expression group,and the differences were statistically significant (P＜0.05).Conclusion The high expression of PD-1 and LAG-3 is related to the higher level of clinical test indexes and poor survival prognosis of FL patients.Immune checkpoints such as PD-1 and LAG-3 are co-expressed in the tumor microenvironment and affect T cell counts.

Key words： Programmed death receptor-1 Lymphocyte activation gene-3 Tumor microenvironment Follicular lymphoma

通讯作者: 丁凯阳（1974-），男，安徽合肥人，博士，主任医师；研究方向：淋巴瘤及骨髓瘤。

作者简介: 倪金菊（1998-），女，安徽合肥人，硕士；研究方向：淋巴瘤及骨髓瘤。

引用本文:

倪金菊;王馨辰; 胡茂贵;张瑰红; 丁凯阳. 程序性死亡受体-1 与淋巴细胞活化基因-3在滤泡性淋巴瘤中的表达及临床意义[J]. 中国当代医药, 2024, 31(18): 14-20.
NI Jinju1 WANG Xinchen2 HU Maogui2 ZHANG Guihong3 DING Kaiyang1. Expression and clinical significance of programmed death receptor-1 and lymphocyte activation gene-3 in follicular lymphoma. 中国当代医药, 2024, 31(18): 14-20.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2024/V31/I18/14

[1]	Gordon MJ，Smith MR，Nastoupil LJ.Follicular lymphoma：The long and winding road leading to your cure?[J].Blood Rev，2023，57：100992.
[2]	Li Y，Zhang Y，Wang W，et al.Follicular Lymphoma in China：Systematic Evaluation of Follicular Lymphoma Prognostic Models[J].Cancer Manag Res，2022，14：1385-1393.
[3]	Xie M，Jiang Q，Zhao S，et al.Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma：A meta-analysis[J].Int Immunopharmacol，2020，85：106684.
[4]	Jacobsen E.Follicular lymphoma：2023 update on diagnosis and management[J].Am J Hematol，2022，97（12）：1638-1651.
[5]	Maeshima AM.Histologic transform ation of follicular lymphoma：pathologists' viewpoint[J].J Clin Exp Hematop，2023，63（1）：12-18.
[6]	Casulo C.Response-Adapted Therapy in Follicular Lymphoma：At the Threshold of a Precision Approach[J].J Clin Oncol，2022，40（7）：698-701.
[7]	Batlevi CL，Sha F，Alperovich A，et al.Follicular lymphoma in the modern era：survival，treatment outcomes，and identification of high-risk subgroups[J].Blood Cancer J，2020，10（7）：74.
[8]	Beck Enemark M，Monrad I，Madsen C，et al.PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation[J].Onco Targets Ther，2021，14：481-489.
[9]	Sabattini E，Bacci F，Sagramoso C，et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008：an overview[J].Pathologica，2010，102（3）：83-87.
[10]	Armitage JO.Staging non-Hodgkin lymphoma[J].CA Cancer J Clin，2005，55（6）：368-376.
[11]	Solal-Céligny P，Roy P，Colombat P，et al.Follicular lymphoma international prognostic index[J].Blood，2004，104（5）：1258-1365.
[12]	Liu SM，Meng Q，Zhang QX，et al.Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma[J].Zhonghua Zhong Liu Za Zhi，2008，30（3）：192-195.
[13]	Chen BJ，Dashnamoorthy R，Galera P，et al.The immune checkpoint molecules PD-1，PD-L1，TIM-3 and LAG-3 in diffuse large B-cell lymphoma[J].Oncotarget，2019，10（21）：2030-2040.
[14]	Liu XY，Yuan XL，Ma RJ，et al.[Expression of PD-1，TIM-3，LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis][J].Zhonghua Yi Xue Za Zhi，2020，100（36）：2846-2853.
[15]	Tamma R，Ingravallo G，Annese T，et al.Tumor Microenvironment and Microvascular Density in Follicular Lymphoma[J].J Clin Med，2022，11（5）：1257.
[16]	Tamma R，Ingravallo G，Gaudio F，et al.STAT3，tumor microenvironment，and microvessel density in diffuse large B cell lymphomas[J].Leuk Lymphoma，2020，61（3）：567-574.
[17]	Gestermann N，Saugy D，Martignier C，et al.LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures[J].Oncoimmunology，2020，9（1）：1736792.
[18]	Liu Y，Guo X，Zhan L，et al.LAG3 and PD1 Regulate CD8+T Cell in Diffuse Large B-cell Lymphoma Patients[J].Comput Math Methods Med，2021，2021：4468140.
[19]	Fujii K，Sakamoto Y，Masaki A，et al.Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma[J].J Pathol Clin Res，2021，7（1）：52-60.
[20]	Colombo AR，Hav M，Singh M，et al.Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma[J].Blood Adv，2022，6（16）：4675-4690.
[21]	Zhao L，Liu Y，Zhang J，et al.LncRNA SNHG14/miR -5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint[J].Cell Death Dis，2019，10（10）：731.
[22]	Kim S，Kwon D，Koh J，et al.Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified[J].Virchows Arch，2020，477（1）：131-142.
[23]	Tobin JWD，Bednarska K，Campbell A，et al.PD-1 and LAG-3 Checkpoint Blockade：Potential Avenues for Therapy in B-Cell Lymphoma[J].Cells，2021，10（5）：1152.
[24]	Karakatsanis S，Papadatos SS，Syrigos N，et al.Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma，not otherwise specified：Correlationwithclinicalandpathologicalfindings[J].JBuon，2021，26（2）：569-579.
[25]	Kwiecinska A，Tsesmetzis N，Ghaderi M，et al.CD274（PD-L1）/PDCD1（PD-1）expression in de novo and transformed diffuse large B-cell lymphoma[J].Br J Haematol，2018，180（5）：744-748.
[26]	Murakami S，Kato H，Higuchi Y，et al.Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisolone in first-line chemotherapy[J].Ann Hematol，2016，95（8）：1259-1269.
[27]	Zhou Y，Qin Y，He X，et al.Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era：A China single-center retrospective study[J].Asia Pac J Clin Oncol，2021，17（3）：289-299.
[28]	Yang ZZ，Kim HJ，Villasboas JC，et al.Expression of LAG-3 defines exhaustion of intratumoral PD-1+T cells and correlates with poor outcome in follicular lymphoma[J].Oncotarget，2017，8（37）：61425-61439.
[29]	Huuhtanen J，Kasanen H，Peltola K，et al.Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma[J].J Clin Invest，2023，133（6）：e164809.
[30]	Zahm CD，Moseman JE，Delmastro LE，et al.PD -1 and LAG-3 blockade improve anti-tumor vaccine efficacy[J].Oncoimmunology，2021，10（1）：1912892.